Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. (September 2020)
- Record Type:
- Journal Article
- Title:
- Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19. (September 2020)
- Main Title:
- Associations of clinical characteristics and treatment regimens with the duration of viral RNA shedding in patients with COVID-19
- Authors:
- Chen, Xudan
Zhu, Baoyi
Hong, Wenxin
Zeng, Jianwen
He, Xi
Chen, Jingfeng
Zheng, Haipeng
Qiu, Shuang
Deng, Ying
Chan, Juliana C.N.
Wang, Jian
Zhang, Yuying - Abstract:
- Highlights: The median duration of viral RNA shedding was 12 days, with a few cases showing shedding for up to 5–6 weeks. Delayed hospital admission resulted in prolonged viral RNA shedding. Old age and diarrhea as a symptom were associated with prolonged viral RNA shedding. Corticosteroid should be used with caution due to the risk of delayed viral RNA clearance. Lopinavir/ritonavir tended to delay viral RNA clearance in patients with non-severe illness. Abstract: Objective: The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, but the factors influencing viral RNA shedding, which would help inform optimal control strategies, remain unclear. Methods: The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were evaluated retrospectively. Results: The median duration of viral RNA shedding was 12 days (interquartile range 8–16 days) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA clearance within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.98–1.00; p = 0.04), time lag from illness onset to hospital admission (HR 0.91, 95% CI 0.88–0.94; p < 0.001), diarrhea (HR 0.59, 95% CI 0.36–0.96; p = 0.036), corticosteroid treatment (HR 0.60, 95% CI 0.39–0.94; p =Highlights: The median duration of viral RNA shedding was 12 days, with a few cases showing shedding for up to 5–6 weeks. Delayed hospital admission resulted in prolonged viral RNA shedding. Old age and diarrhea as a symptom were associated with prolonged viral RNA shedding. Corticosteroid should be used with caution due to the risk of delayed viral RNA clearance. Lopinavir/ritonavir tended to delay viral RNA clearance in patients with non-severe illness. Abstract: Objective: The novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic, but the factors influencing viral RNA shedding, which would help inform optimal control strategies, remain unclear. Methods: The clinical course and viral RNA shedding pattern of 267 consecutive symptomatic COVID-19 patients admitted to the hospital from January 20, 2020 to March 15, 2020 were evaluated retrospectively. Results: The median duration of viral RNA shedding was 12 days (interquartile range 8–16 days) after the onset of illness. Of the 267 patients included in this study, 65.2% had viral RNA clearance within 14 days, 88.8% within 21 days, and 94.4% within 28 days. Older age (hazard ratio (HR) 0.99, 95% confidence interval (CI) 0.98–1.00; p = 0.04), time lag from illness onset to hospital admission (HR 0.91, 95% CI 0.88–0.94; p < 0.001), diarrhea (HR 0.59, 95% CI 0.36–0.96; p = 0.036), corticosteroid treatment (HR 0.60, 95% CI 0.39–0.94; p = 0.024), and lopinavir/ritonavir use (HR 0.70, 95% CI 0.52–0.94; p = 0.014) were significantly and independently associated with prolonged viral RNA shedding. Conclusions: Early detection and timely hospital admission may be warranted for symptomatic COVID-19 patients, especially for older patients and patients with diarrhea. Corticosteroid treatment is associated with prolonged viral RNA shedding and should be used with caution. Lopinavir/ritonavir use may be associated with prolonged viral RNA shedding in non-severe patients; further randomized controlled trials are needed to confirm this finding. … (more)
- Is Part Of:
- International journal of infectious diseases. Volume 98(2020)
- Journal:
- International journal of infectious diseases
- Issue:
- Volume 98(2020)
- Issue Display:
- Volume 98, Issue 2020 (2020)
- Year:
- 2020
- Volume:
- 98
- Issue:
- 2020
- Issue Sort Value:
- 2020-0098-2020-0000
- Page Start:
- 252
- Page End:
- 260
- Publication Date:
- 2020-09
- Subjects:
- Corticosteroid -- COVID-19 -- Diarrhea -- Lopinavir/ritonavir -- Risk factors -- Viral RNA shedding
Communicable diseases -- Periodicals
Communicable Diseases -- Periodicals
Communicable diseases
Periodicals
Electronic journals
616.9 - Journal URLs:
- http://bibpurl.oclc.org/web/73769 ↗
http://www.journals.elsevier.com/international-journal-of-infectious-diseases/ ↗
http://www.sciencedirect.com/science/journal/12019712 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/12019712 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/12019712 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.ijid.2020.06.091 ↗
- Languages:
- English
- ISSNs:
- 1201-9712
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4542.304750
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 14006.xml